UK markets close in 7 hours 45 minutes

Atossa Therapeutics, Inc. (ATOS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.9000+0.1200 (+4.32%)
At close: 4:00PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5362.14M
Enterprise value 3219.71M
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)2.51
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7-12.05

Trading information

Stock price history

Beta (5Y monthly) 2.25
52-week change 347.87%
S&P500 52-week change 331.55%
52-week high 39.8000
52-week low 30.8100
50-day moving average 33.3435
200-day moving average 33.6599

Share statistics

Avg vol (3-month) 37.27M
Avg vol (10-day) 34.08M
Shares outstanding 5126.62M
Implied shares outstanding 6N/A
Float 8126.6M
% held by insiders 10.04%
% held by institutions 131.42%
Shares short (29 Sept 2021) 422.28M
Short ratio (29 Sept 2021) 43.4
Short % of float (29 Sept 2021) 417.60%
Short % of shares outstanding (29 Sept 2021) 417.59%
Shares short (prior month 30 Aug 2021) 424.6M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 319 Apr 2018
Ex-dividend date 4N/A
Last split factor 21:12
Last split date 319 Apr 2018

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-14.63%
Return on equity (ttm)-28.27%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -18.23M
Net income avi to common (ttm)-26.05M
Diluted EPS (ttm)-0.4320
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)142.43M
Total cash per share (mrq)1.12
Total debt (mrq)4.72k
Total debt/equity (mrq)0.00
Current ratio (mrq)81.19
Book value per share (mrq)1.14

Cash flow statement

Operating cash flow (ttm)-15.86M
Levered free cash flow (ttm)-9.03M